S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$1.32
+4.8%
$1.45
$0.65
$2.12
$98.63M2.29345,278 shs329,091 shs
LifeMD, Inc. stock logo
LFMD
LifeMD
$10.21
+3.4%
$8.90
$1.40
$12.01
$412.18M1.43828,557 shs856,850 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$6.92
+2.5%
$7.04
$1.62
$9.00
$331.33M0.9186,211 shs250,511 shs
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
$1.23
+5.1%
$1.65
$0.33
$2.66
$91.40M0.68128,107 shs37,757 shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
+9.57%+1.61%-19.23%-2.33%+12.50%
LifeMD, Inc. stock logo
LFMD
LifeMD
-0.50%+0.10%-8.95%+64.50%+473.84%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-5.33%-6.64%-1.17%+28.33%+221.43%
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
+0.86%-17.02%-27.78%-45.33%+119.22%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
2.9414 of 5 stars
3.55.00.00.02.61.70.6
LifeMD, Inc. stock logo
LFMD
LifeMD
0.2126 of 5 stars
1.52.00.00.02.60.80.0
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
1.7821 of 5 stars
3.53.00.00.02.41.70.0
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
2.0007 of 5 stars
3.53.00.00.01.71.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
3.00
Buy$4.75259.85% Upside
LifeMD, Inc. stock logo
LFMD
LifeMD
3.00
Buy$10.20-0.10% Downside
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.00
Buy$12.5080.64% Upside
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
3.00
Buy$2.2582.93% Upside

Current Analyst Ratings

Latest TOI, LFMD, TCRX, and CLSD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/17/2024
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$10.00
4/11/2024
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
3/15/2024
LifeMD, Inc. stock logo
LFMD
LifeMD
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$11.00 ➝ $13.00
3/14/2024
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
3/13/2024
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$5.00
3/13/2024
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$5.00 ➝ $4.00
3/7/2024
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
3/6/2024
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$9.00 ➝ $10.00
2/26/2024
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$9.00
2/26/2024
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$2.50
2/1/2024
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$9.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$8.23M11.98N/AN/A($0.25) per share-5.28
LifeMD, Inc. stock logo
LFMD
LifeMD
$152.55M2.70N/AN/A$0.15 per share68.07
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$21.05M15.74N/AN/A$3.15 per share2.20
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
$324.24M0.28N/AN/A$0.77 per share1.60

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$32.49M-$0.53N/AN/AN/A-394.91%N/A-85.31%5/9/2024 (Estimated)
LifeMD, Inc. stock logo
LFMD
LifeMD
-$20.60M-$0.70N/AN/AN/A-14.01%N/A-50.74%5/10/2024 (Estimated)
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$89.22M-$1.89N/AN/AN/A-423.86%-60.65%-33.86%5/8/2024 (Estimated)
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
-$83.07M-$0.92N/AN/AN/A-24.56%-80.46%-28.14%5/8/2024 (Estimated)

Latest TOI, LFMD, TCRX, and CLSD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/12/2024Q4 2023
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$0.10-$0.08+$0.02-$0.08$3.40 million$6.35 million
3/11/2024Q4 2023
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.14-$0.12+$0.02-$0.12$40.65 million$44.86 million
3/6/202412/31/2023
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.29-$0.21+$0.08-$0.21$2.94 million$7.21 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/AN/AN/AN/AN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/A
4.42
4.42
LifeMD, Inc. stock logo
LFMD
LifeMD
3.22
1.22
1.15
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.18
6.51
6.51
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
1.52
4.12
3.73

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
18.75%
LifeMD, Inc. stock logo
LFMD
LifeMD
35.52%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
36.86%

Insider Ownership

CompanyInsider Ownership
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
9.80%
LifeMD, Inc. stock logo
LFMD
LifeMD
18.89%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
8.27%
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
13.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
3074.72 million67.40 millionOptionable
LifeMD, Inc. stock logo
LFMD
LifeMD
20740.37 million32.74 millionOptionable
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
15447.88 million43.92 millionNot Optionable
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
75074.31 million64.58 millionNot Optionable

TOI, LFMD, TCRX, and CLSD Headlines

SourceHeadline
AI tool predicts responses to cancer therapy using information from each cell of the tumorAI tool predicts responses to cancer therapy using information from each cell of the tumor
medicalxpress.com - April 18 at 1:41 PM
New trial shows immunotherapy post-surgery improves overall survival for kidney cancerNew trial shows immunotherapy post-surgery improves overall survival for kidney cancer
medicalxpress.com - April 18 at 8:40 AM
Colon cancer rates are rising in young people. If you have two symptoms you should get a colonoscopy, a GI oncologist says.Colon cancer rates are rising in young people. If you have two symptoms you should get a colonoscopy, a GI oncologist says.
msn.com - April 18 at 8:40 AM
Topicus.com Inc. Announces Release Date for First Quarter ResultsTopicus.com Inc. Announces Release Date for First Quarter Results
markets.businessinsider.com - April 18 at 3:39 AM
Florida system raises $93M for cancer instituteFlorida system raises $93M for cancer institute
beckershospitalreview.com - April 15 at 1:28 PM
Rheumatologists join oncology space to treat debilitating side effects without affecting cancer controlRheumatologists join oncology space to treat debilitating side effects without affecting cancer control
highlandcountypress.com - April 13 at 6:29 PM
Study Provides First Look at Oncologists’ Views on Ethical Implications of AI in Cancer CareStudy Provides First Look at Oncologists’ Views on Ethical Implications of AI in Cancer Care
cancerhealth.com - April 13 at 6:29 PM
Avinash Reddy confident of his hat-trick at Kadapa parliament despite onslaught unleashed by YS sistersAvinash Reddy confident of his hat-trick at Kadapa parliament despite onslaught unleashed by YS sisters
timesofindia.indiatimes.com - April 13 at 6:29 PM
Daily healthy habits to reduce cancer riskDaily healthy habits to reduce cancer risk
msn.com - April 10 at 8:21 AM
Jordan McInerney Appointed as Chief Development Officer of The Oncology InstituteJordan McInerney Appointed as Chief Development Officer of The Oncology Institute
finance.yahoo.com - April 8 at 10:07 AM
Kent Lake Capital LLC Buys 901,956 Shares of The Oncology Institute, Inc. (NASDAQ:TOI)Kent Lake Capital LLC Buys 901,956 Shares of The Oncology Institute, Inc. (NASDAQ:TOI)
marketbeat.com - April 6 at 7:36 PM
The Oncology Institute and Healthly Forge Strategic Alliance to Elevate Cancer Care Access to Healthly Patients Across Southern CaliforniaThe Oncology Institute and Healthly Forge Strategic Alliance to Elevate Cancer Care Access to Healthly Patients Across Southern California
globenewswire.com - April 4 at 8:00 AM
Centre for early cancer detection is gifted £11mCentre for early cancer detection is gifted £11m
msn.com - April 4 at 1:03 AM
Deaths foretoldDeaths foretold
timesofindia.indiatimes.com - April 3 at 12:01 AM
Study finds AI empowers patients before and after seeing physicians for radiation oncology treatmentStudy finds AI empowers patients before and after seeing physicians for radiation oncology treatment
msn.com - April 2 at 7:01 PM
Man dies after 3 hospitals deny entry in DelhiMan dies after 3 hospitals deny entry in Delhi
msn.com - April 2 at 3:59 AM
Man Dies After 3 Hosps Deny EntryMan Dies After 3 Hosps Deny Entry
timesofindia.indiatimes.com - April 1 at 10:59 PM
The Oncology Institute, Inc. (NASDAQ:TOI) Q4 2023 Earnings Call TranscriptThe Oncology Institute, Inc. (NASDAQ:TOI) Q4 2023 Earnings Call Transcript
finance.yahoo.com - April 1 at 5:58 PM
How an Indian-made cervical cancer vaccine can save 2 lakh livesHow an Indian-made cervical cancer vaccine can save 2 lakh lives
timesofindia.indiatimes.com - March 31 at 9:37 PM
Are we over-looking elderly loneliness?Are we over-looking elderly loneliness?
msn.com - March 30 at 3:33 PM
We are so grateful: Indian-origin teen first to get UKs life-changing cancer treatment'We are so grateful': Indian-origin teen first to get UK's life-changing cancer treatment
timesofindia.indiatimes.com - March 30 at 3:33 PM
For unity in Covid fight, called for clanging utensils, despite ridicule: PM ModiFor unity in Covid fight, called for clanging utensils, despite ridicule: PM Modi
msn.com - March 29 at 8:34 PM
Oncology Institute Full Year 2023 Earnings: US$0.92 loss per share (vs US$0.001 profit in FY 2022)Oncology Institute Full Year 2023 Earnings: US$0.92 loss per share (vs US$0.001 profit in FY 2022)
finance.yahoo.com - March 29 at 10:33 AM
Milwaukee’s Top Cancer Doctors 2024Milwaukee’s Top Cancer Doctors 2024
milwaukeemag.com - March 28 at 8:41 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Clearside Biomedical logo

Clearside Biomedical

NASDAQ:CLSD
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
LifeMD logo

LifeMD

NASDAQ:LFMD
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.
TScan Therapeutics logo

TScan Therapeutics

NASDAQ:TCRX
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Oncology Institute logo

Oncology Institute

NASDAQ:TOI
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates in three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient blood product transfusions, and patient support services. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.